EDAP TMS S.A. ( (EDAP) ) has released its Q2 earnings. Here is a breakdown of the information EDAP TMS S.A. presented to its investors.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
EDAP TMS S.A. is a global leader in robotic energy-based therapies, specializing in the development, manufacturing, and distribution of minimally invasive medical devices using ultrasound technology, primarily for prostate cancer treatment.
In its latest earnings report, EDAP TMS S.A. announced a strong performance for the second quarter of 2025, highlighted by a significant year-over-year growth in its High-Intensity Focused Ultrasound (HIFU) segment. The company reported a 76.8% increase in HIFU revenue and a 140% growth in net placements of its Focal One systems.
Key financial metrics revealed that the company’s total worldwide revenue for the second quarter of 2025 was EUR 16.0 million, a slight increase from the previous year. The HIFU business, in particular, showed robust growth with revenues reaching EUR 8.5 million, driven by increased sales of Focal One systems. However, the non-core business segments experienced a decline, aligning with the company’s strategic focus on its core HIFU operations. Despite a net loss of EUR 5.6 million for the quarter, the company improved its gross profit margin to 42.5%, up from 37.5% in the previous year.
Strategically, EDAP TMS S.A. has executed a letter of intent for a EUR 36 million credit facility with the European Investment Bank to further accelerate its HIFU growth and strategic expansion. Additionally, the company has raised its 2025 HIFU revenue growth guidance to a range of 26% to 34%.
Looking ahead, EDAP TMS S.A. remains optimistic about the continued demand for its Focal One platform, supported by recent clinical studies and the anticipated expansion into new indications. The company is poised to strengthen its market position as it transitions to a U.S. domestic filer by January 2026, complying with U.S. SEC reporting rules and Nasdaq listing requirements.